293780 — AptaBio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩285bn
- KR₩281bn
- KR₩324m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -6,298 | -3,919 | -10,689 | -10,565 | -19,098 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 101 | -1,424 | -90.1 | 1,715 | 3,258 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 120 | 1,333 | 1,562 | 1,557 | 1,244 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -6,002 | -3,785 | -8,897 | -6,833 | -14,095 |
Capital Expenditures | -3,740 | -2,076 | -169 | -1,186 | -167 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -40,794 | 2,448 | 1,302 | 2,929 | -12,570 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -44,534 | 371 | 1,133 | 1,743 | -12,737 |
Financing Cash Flow Items | -3,567 | 39.5 | -356 | -5.24 | -19.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 62,814 | 1,508 | -376 | 496 | 49,854 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 12,290 | -1,915 | -8,120 | -4,577 | 23,027 |